Description

Irinotecan Medac for Infusions 20 mg/ml. 2 ml. (40 mg.)

Ingredients

Active ingredient: Irinotecan hydrochloride trihydrate.

Dosage

Dosage: The recommended dosage of Irinotecan Medac for infusions is determined by the patient’s body surface area and general health condition. It is administered intravenously over a specific period as directed by a healthcare professional.

Indications

Indications: Irinotecan Medac is indicated for the treatment of colorectal cancer that has spread to other parts of the body. It is often used in combination with other chemotherapy medications.

Contraindications

Contraindications: Irinotecan Medac is contraindicated in patients with a known hypersensitivity to irinotecan or any of the other ingredients in the formulation. It should not be used in patients with severe bone marrow suppression.

Directions

Directions: Irinotecan Medac should only be administered by healthcare professionals experienced in the use of chemotherapy medications. The infusion should be given slowly to reduce the risk of side effects.

Scientific Evidence

Scientific evidence: Several clinical studies have demonstrated the efficacy of Irinotecan in the treatment of advanced colorectal cancer. A study published in the Journal of Clinical Oncology showed that Irinotecan, when used in combination with other chemotherapy agents, significantly improved overall survival rates in patients with metastatic colorectal cancer.

Additional Information

Pharmacological effects: Irinotecan works by inhibiting the enzyme topoisomerase I, which is involved in DNA replication. By interfering with this process, Irinotecan prevents cancer cells from dividing and growing, ultimately leading to cell death.

Clinical trials: Clinical trials have shown that Irinotecan, when used in combination with other chemotherapy drugs, can improve response rates and prolong survival in patients with advanced colorectal cancer. These trials have established Irinotecan as a key component in the treatment of this disease.